Ganesh Dhavalshankh1, Archana Dhavalshankh2*
1Professor and Head, Dept. of Dermatology, RCSMGMC, Kolhapur ,Maharashtra, India
2Professor and Head, Dept. of Pharmacology, D Y Patil Medical College, Kolhapur, Maharashtra, India
*Address for Corresponding author
Professor and head,
Department of Pharmacology, D Y Patil Medical College, Kolhapur, Maharashtra, India
Background- Diarrhea is frequently observed in moderate to severe plaque Psoriasis patients treated with Aprimilast. Though, it is known about the Apremilast associated diarrhea in but dose related prevalence varies in patients of psoriasis. Objective: To estimate the Prevalence of Apremilast associated diarrhea in mod to severe plaque psoriasis patients receiving various doses of Apremilast. Materials and Methods: The study was done in 152 Psoriasis patients attending skin and V.D. department in a tertiary care center receiving Apremilast treatment in dose of 30 mg twice a day to estimate the prevalence of diarrhea. Results: The prevalence of grade I diarrhea was 67% and 53%, grade II was 9% and 4% in male and female respectively. The grade III diarrhea was 2% both in male and female whereas grade IV diarrhea reported in male (1%) patient only. The Study data suggested that the diarrhea after Apremilast therapy is self-limiting and 4% discontinued therapy after diarrhea. Conclusion: It was observed that most of the Psoriasis patients receiving Apremilast suffered from diarrhea but these patients should be counselled and monitored regularly for Apremilast induced diarrhea.
Keywords: Plaque psoriasis, apremilast, diarrhea, gastrointestinal